Improvement of Sorafenib Solubility By Different Solid Dispersion Techniques
Abstract
The present work aimed to enhance the solubility and dissolution of the poorly water-soluble drug, sorafenib (SFN), by solid dispersion (SD) techniques. Solid dispersions of sorafenib were prepared by three different techniques, namely surface solid dispersions (SSD1-SSD15), melt granulation (MG1-MG15), liquisolid compacts (LSC1-LSC 9). All the formulations were evaluated for pre-formulation studies, solubility studies, percentage practical yield, % drug content, and in-vitro drug release. The best formulation based on drug release was further characterized for FTIR, XRD, SEM and stability studies. The formulations prepared by surface solid dispersions (SSD1-SSD15), melt granulation (MG1-MG15), liquisolid compacts (LSC1-LSC9) exhibited enhanced drug release compared to pure drug. Among all the formulations, sorafenib prepared by Melt Granulation technique (MG 3) showed highest drug release of 99.89%. The order of preference for solid dispersions prepared by different techniques was MG 3 > LSC 1 > SSD 3. The formulation MG 3 was further characterized for FTIR, where no significant changes were observed, suggesting no interactions between drug and excipients. X-ray diffraction studies revealed the conversion of sorafenib from the crystalline state to the amorphous, which was further supported by scanning electron microscopy. Stability studies proved the formulation was stable for 3 months. These findings suggest that the preparation of sorafenib solid dispersions using Melt Granulation technique could be a promising strategy for improvement of solubility and dissolution. Low cost, simple processing and great potentials in industrial production are the main advantages of this approach. In addition to enhancing the dissolution rate of poorly water-soluble drugs, this technique is also a fairly new technique to effectively retard drug release.
Keywords:
Sorafenib, Tumour, Solid Dispersions, Solubility, Liquisolid CompactDOI
https://doi.org/10.25004/IJPSDR.2022.140301References
Pandya P, Gattani S, Jain P, Khirwal L, Surana S. Co-solvent Evaporat ion Method for Enhancement of Solubi lit y and Dissolution Rate of Poorly Aqueous Soluble Drug Simvastatin: In vitro–In vivo Evaluation. AAPS Pharm Sci Tech. 2008; 9:1247- 1252. Available from: doi: 10.1208/s12249-008-9176-z.
Jun HP, Hoo KC. Enhancement of solubility and dissolution of Cilostazol by solid dispersion technique. Archives of Pharmacal Res. 2015; 38:1336–44.
Liu L, Cao, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66 (24): 11851–11858. Available from: https://doi.org/10.1158/0008- 5472.CAN-06-1377
Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay C, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. The oncologist. 2009;14: 95-100. Available from: DOI: 10.1634/theoncologist.2008-0185
Wang XQ, Fan JM, Liu O, Zhao B, Jia ZR, Zhang Q. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011; 419:339-346. Available from: DOI: 10.1016/j.ijpharm.2011.08.003
Yosra SRE, Magda AE, Ossama YA. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm. 2009; 380 (1-2):133–141. Available from: DOI: 10.1016/j. ijpharm.2009.07.015
Anand Kumar Meka, Santhosh Pola, Karnaker Reddy Tupally, Prasanna Lakshmi Abbaraju. Development, evaluation and characterization of surface solid dispersion for solubility and dissolution enhancement of irbesartan. Int J Drug Dev Res. 2022; 4:263-273
Chengyu Liu, Zhen Chen, Yuejie Chen, Jia Lu, Yuan Li, Shujing Wang, Guoliang Wu, and Feng Qian. Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms. Mol.Pharm. 2016; 13 (2): 599-608. Available from: ht tps://doi.org/10.1021/acs. molpharmaceut.5b00837
Vinod M, Jitendra N, Komal P, Rahul C, Gokul K. Enhancement of solubility with formulation and in-vitro evaluation of oral sorafenib compacts by liquisolid technique. Adv Diabetes Metab. 2013; 1:57- 64. Available from: DOI: 10.13189/adm.2013.010302
Nagaraju Diddi, Shravan KY, Pavani S, Neelima P. Formulation and Evaluation of Liquid Nanocrystals of Sorafenib Tosylate. Glob J Pharmaceu Sci. 2019;7(5):137-142. Available from DOI: 10.19080/ GJPPS.2019.07.555721
Yang D, Kulkarni R, Behme RJ, Kotiyan PN. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. Int J Pharm. 2007; 329(1-2):72-80. Available from: DOI: 10.1016/j.ijpharm.2006.08.029
Friedrich H, Fussnegger B, Kolter K, Bodmeier R Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm 2006; 62 (2): 171-177. Available from: DOI: 10.1016/j.ejpb.2005.08.013
Spireas S, Wang T, Grover R Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm 1999; 25: 163-168. Available from: DOI: 10.1081/ddc-100102156
Kumar, Prasanna & Bonthagarala, Brahmaiah & Rao, Pasam. Formulation and evaluation of Nateglinide dispersible tablet by direct compression method. Int J of Adva in Sci Res. 2015; 1:51-56.
Hentzschel CM, Alnaief M, Smirnova I, Sakmann A. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm. 2012; 80:130-135. Available from: DOI: 10.1016/j. ejpb.2011.08.001
Tellagorla Thriveni. Formulation and Evaluation Of Sustained Release Effervescent Floating Tablets of Nateglinide IOSR Journal of pharmacy.2018; 8(4): 45-54.
Wairkar S, Gaud R. Co-Amorphous Combination of Sorafenib- Metformin Hydrochloride for Dissolution Enhancement. AAPS PharmSciTech.2016; 17:673–681.
Published
Abstract Display: 935 
PDF Downloads: 543 
